Assembly Biosciences announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, its orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate. This study will evaluate the safety, tolerability, and pharmacokinetics of ABI-6250 across single and multiple ascending dose cohorts in healthy participants.
The Phase 1a study will also assess serum bile acids as a biomarker of ABI-6250’s engagement of its target, the sodium taurocholate cotransporting polypeptide (NTCP). Data from this Phase 1a study are expected in Q3 2025.
ABI-6250 has the potential to be the first oral therapy for chronic HDV, a life-threatening chronic viral infection with limited treatment options. Preclinical studies showed ABI-6250's low nanomolar potency across multiple HDV genotypes and a pharmacokinetic profile supporting once-daily oral dosing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.